What disease does Mosunetuzumab treat?

Mosunetuzumab (Mosunetuzumab) is a drug that belongs to the field of immunotherapy. Specifically, it is a type of immune checkpoint inhibitor. The development of this drug represents a major breakthrough in cancer treatment and provides new treatment options for some patients with malignant tumors. The properties, mechanisms, and applications of motuzumab will be described in detail below.

Motuzumab is a humanized monoclonal antibody that is administered intravenously. What makes it unique is its bispecific antibody structure, which targets two different proteins, CD3 and CD20 simultaneously. CD3 exists on the surface of T cells, while CD20 mainly exists on the surface of B cells, including malignant B cells. This allows motuzumab to connect T cells and B cells, prompting T cells to actively attack malignant B cells while reducing damage to normal cells.

The primary indication for motuzumab is the treatment of diffuse large B cell lymphoma (DLBCL), a common subtype of B cell malignancy. It is commonly used in adults with refractory or relapsed DLBCL, especially those who are no longer responsive to traditional treatments. Motuzumab treatment regimens are typically administered intravenously and can be completed in a relatively short period of time, thereby improving the patient's quality of life.

Although motuzumab represents an innovative approach to cancer treatment, it may be associated with side effects such as fever, chills, nausea, fatigue, etc. Therefore, before using motuzumab, doctors will develop a personalized treatment plan based on the patient's specific situation and overall health, and closely monitor the patient's response.